Jefferies Financial Group Inc. purchased a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,000 shares of the company's stock, valued at approximately $570,000.
Other large investors have also recently bought and sold shares of the company. Jones Financial Companies Lllp lifted its stake in shares of BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after acquiring an additional 246 shares during the period. Quintet Private Bank Europe S.A. raised its holdings in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE acquired a new stake in BioNTech in the fourth quarter valued at about $90,000. Generali Investments CEE investicni spolecnost a.s. purchased a new stake in BioNTech in the 4th quarter valued at approximately $137,000. Finally, AlphaCentric Advisors LLC purchased a new stake in BioNTech in the 4th quarter valued at approximately $168,000. Institutional investors and hedge funds own 15.52% of the company's stock.
Analysts Set New Price Targets
A number of analysts recently weighed in on BNTX shares. HC Wainwright restated a "buy" rating and issued a $134.00 price target (down from $145.00) on shares of BioNTech in a research note on Wednesday, May 14th. Morgan Stanley lowered their price target on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. Citigroup reissued a "buy" rating and set a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Finally, BMO Capital Markets increased their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, BioNTech has a consensus rating of "Moderate Buy" and an average price target of $142.08.
View Our Latest Stock Analysis on BioNTech
BioNTech Stock Performance
BNTX stock traded up $3.92 during mid-day trading on Tuesday, reaching $101.72. 1,812,605 shares of the stock traded hands, compared to its average volume of 935,411. The firm has a market capitalization of $24.45 billion, a PE ratio of -48.44 and a beta of 1.35. The business has a 50-day moving average of $97.36 and a two-hundred day moving average of $108.72. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.
BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the previous year, the company posted $1.90 earnings per share. The company's quarterly revenue was down 19.5% compared to the same quarter last year. As a group, equities analysts predict that BioNTech SE will post -3.88 EPS for the current fiscal year.
About BioNTech
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Articles
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
